Neutralization profiles of sera from human immunodeficiency virus (HIV)- infected individuals: Relationship to HIV viral load and CD4 cell count

Clinical and Diagnostic Laboratory Immunology

Volumn 7, Issue 3, 2000, Pages 412-416

  Nokta, Mostafa ^a,b   Turk, Patricia ^a   Loesch, Kimberly ^a   Pollard, Richard B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIVIG; NEUTRALIZING ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MEDICAL DECISION MAKING; PHENOTYPE; PRIORITY JOURNAL; SERUM; TREATMENT PLANNING; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV; HIV ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOPHENOTYPING; MALE; MUTATION; NEUTRALIZATION TESTS; RNA, VIRAL; SPECIES SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 0034019766     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.7.3.412-416.2000     Document Type: Article

References (31)

1. Albert, J., B. Abrahamson, K. Nagy, E. Aurelius, H. Gaines, G. Nystrom, and E. M. Fenyo. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autolugous sera. AIDS 4:107-118.
2. Arendrup, M., C. Nielsen, J. Hansen, C. Pedersen, L. Mathiesen, and J. O. Nielsen. 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5:303-307.
3. Balfe, P., P. Simmonds, C. A. Ludlam, J. O. Bishop, and A. J. L. Brown. 1990. Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. J. Virol. 64:6221-6233.
4. Bongertz, V., C. L. Costa, V. G. V. Santos, E. C. J. Filho, B. Galvao-Castro, M. G. Morgado, and the Hospital Evandro Chagas AIDS Clinical Research Group. 1997. Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. AIDS 11:969-975.
5. Cecilia, D., V. N. Kewalramani, J. O'Leary, B. Volsky, P. Nyambi, S. Burda, S. Xu, D. R. Littman, and S. Zolla-Pazner. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72:6988-6996.
6. Connor, R. I., H. Mohri, Y. Cao, and D. D. Ho. 1993. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol. 67:1772-1777.
7. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1994. ACTG virology manual for HIV laboratories. National Institute of Allergy and Infectious Diseases publication NIH-94-3828. National Institute of Allergy and Infectious Diseases, Bethesda, Md.
8. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1997. ACTG virology manual for HIV laboratories. National Institute of Allergy and Infectious Diseases publication NIH-97-3828. National Institute of Allergy and Infectious Diseases, Bethesda, Md.
9. Fouchier, R. A. M., M. Groenink, N. A. Kootstra, M. Tersmette, H. G. Huisman, F. Miedema, and H. Schuitemaker. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.
10. Freed, E. O., D. J. Myers, and R. Risser. 1991. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J. Virol. 65:190-194.
11. Goudsmit, J., C. Debouk, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and C. D. Gajdusek. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478-4482.
12. Hahn, B. H., G. M. Shaw, M. E. Taylor, R. R. Redfield, P. D. Markham, S. Z. Salahuddin, F. Wong-Staal, R. C. Gallo, E. S. Parks, and W. P. Parks. 1986. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 232:1548-1553.
13. Hogervorst, E., J. de Jong, A. van Wijk, M. Bakker, M. Valk, P. Nara, and J. Goudsmit. 1995. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies. J. Virol. 69:6342-6351.
14. Ivanoff, L. A., D. J. Looney, C. McDanal, J. F. Morris, F. Wong-Staal, A. J. Langlois, S. R. Petteway, Jr., and T. J. Matthews. 1991. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res. Hum. Retrovir. 7:595-603.
15. Javaherian, K., A. J. Langlois, C. B. McDanal, K. L. Ross, L. I. Eckler, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi, and S. D. Putney. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
16. Kuiken, C. L., J.-J. de Jong, E. Baan, W. Keulen, M. Tersmette, and J. Goudsmit. 1992. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J. Virol. 66:4622-4627.
17. LaCasse, R. A., K. E. Follis, T. Moudgil, M. Trahey, J. M. Binley, V. Planelles, S. Zolla-Pazner, and J. H. Nunberg. 1998. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J. Virol. 72:2491-2495.
18. LaRosa, G., J. P. Davide, K. Wenhold, J. A. Waterbury, A. T. Profy, J. A. Lewis, A. J. Langlois, G. R. Dreesman, R. N. Boswell, and P. Shadduck. 1990. Conserved sequence and structural elements in the HIV-1 principal neutralizing domain. Science 249:932-935.
19. Lathey, J. L., J. Tsou, K. Brinker, K. Hsia, W. A. Meyer, and S. A. Spector. 1999. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J. Infect. Dis. 180:344-350.
20. Leigh-Brown, A. J. 1991. Sequence variability in human immunodeficiency viruses: pattern and process in viral evolution. AIDS 5(Suppl. 2):S535-S542.
21. Montefiori, D. C., R. G. Collman, T. R. Fouts, J. Y. Zhou, M. Bilska, J. A. Hoxie, J. P. Moore, and D. P. Bolognesi. 1998. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J. Virol. 72: 1886-1893.
22. Myers, L. E., L. J. McQuay, and F. B. Hollinger. 1994. Dilution assay statistics. J. Clin. Microbiol. 32:732-739.
23. Nara, P. L., L. Smit, N. Dunlop, W. Hatch, M. Merges, D. Waters, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. 1990. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64:3779-3791.
24. Phillips, R. E., S. Rowland-Jones, D. F. Dixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, and C. R. Rizza. 1991. Human immunodeficiency virus genetic variations that can escape cytotoxic T-cell recognition. Nature 354:453-459.
25. Schonning, K., C. Nielsen, J. Iversen, J. O. Nielsen, and J.-E. S. Hansen. 1995. Neutralizing antibodies in slowly progressing HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:400-407.
26. Schuitemake, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. Y. de Goede, R. P. van Steenwijk, J. M. A. Lange, J. K. M. E. Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66:1354-1360.
27. Scott, W. A., D. Brambilla, E. Siwak, C. Beatty, J. Bremer, R. W. Coombs, H. Farzadegan, S. A. Fiscus, S. M. Hammer, F. B. Hollinger, N. Khan, S. Rasheed, P. S. Reichelderfer, and Participating Laboratories of the AIDS Clinical Trials Group. 1996. Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. J. Clin. Microbiol. 34:2312-2315.
28. Spouge, J. L. 1994. Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies. J. Virol. 68:1782-1789.
29. Trkola, A., T. Ketas, V. N. Kewalramani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Littman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885.
30. Wolfs, T. F. W., G. Zwart, M. Baker, M. Valk, C. L. Kuiken, and J. Goudsmit. 1991. Naturally occurring mutations within the HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 185:195-205.
31. Wrin, T., L. Crawford, L. Sawyer, P. Weber, H. W. Sheppard, and C. V. Hanson. 1994. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 7:211-219.